Business
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely
About this update from Nuvalent, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655. The poster will be presented at the European Lung Cancer Congress (ELCC 2023), taking place in Copenhagen, Denmark, and virtually, March 29 – April 1, 2023.\n\n \n \n \n \n \n \n\n \nThe \"Trial in Progress\" poster includes background and study design considerations for the ALKOVE-1 Phase 1/2 study (NCT05384626) evaluating the safety and preliminary activity of NVL-655 in patients with solid tumors harboring oncogenic ALK alterations, including those with acquired ALK resistance mutations and CNS metastases. The first-in-human, multicenter, open-label, dose-escalation and expansion study is currently evaluating NVL-655 as an oral monotherapy in the Phase 1 portion.\nThe poster will be archived on the Nuvalent website at www.nuvalent.com following the presentation.\nDetails for the poster presentation are as follows:\nTitle: NVL-655, a Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor, in Patients with Advanced ALK-Positive Solid Tumors: The Phase 1/2 ALKOVE-1 Study Authors: Melissa Johnson1, Sai-Hong Ignatius Ou2, Enriqueta Felip3, Christina Baik4, Benjamin Besse5, Julien Mazieres6, D. Ross Camidge7, Shirish Gadgeel8, Alexander Drilon9, Yasir Elamin10, Geoffrey Liu11, Joshua E. Reuss12, Tina Kehrig13, Henry E. Pelish13, Viola Zhu13, Jessica J. Lin14Presentation Number: 81TiPAbstract Category: Advanced NSCLCSession Date and Time: Friday, March 31, 2023 from 12:00 – 12:45pm CESTLocation: Bella Center Copenhagen, Exhibition and Poster Area\n1Sarah Cannon Research Institute, Nashville, TN, United States of America, 2University of California Irvine Medical Center, Orange, CA, United States of America, 3Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, 4Fred Hutchinson Cancer Center, Seattle, WA, United States of America, 5Institut Gustave Roussy, Villejuif, France, 6Institut Universitaire du Cancer, Toulouse, France, 7University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, CO, United States of America, 8Henry Ford Cancer Institu...